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Introduction
V i t a m i n  D ,  t h r o u g h  i t s  a c t i v e  m e t a b o l i t e 
1,25-dihydroxyvitamin D (1,25(OH)2D), plays an essential 
role for translocating dietary Ca across the intestinal 
epithelium, thereby raising the extracellular Ca-Pi product 
to the level required for the adequate mineralization of the 
bone organic matrix. This physiological link explains why 
adequate supplies of both vitamin D and Ca are required to 
support bone health throughout life (1). When their supply 
is insufficient, homeostatic mechanisms operate to prevent 
hypocalcaemia by both stimulating the production and secretion 
of parathyroid hormone (PTH) which, in turn, enhances 
both the renal conservation and the bone resorption of Ca. 
Thus, inadequacy in the vitamin D supply, as expressed by 
a decreased serum 25-hydroxyvitamin D (25OHD), leads 
to secondary hyperparathyroidism (1), and elevated serum 
markers of bone resorption (2). The serum biochemical pattern 
encompassing low 25OHD, high PTH, elevated CTX and 
TRAP5b characterizes the insufficient supply of vitamin D 
associated with low Ca intake, as often observed with aging (3). 
Increasing the supply of both vitamin D and Ca tends to correct 
these biochemical anomalies within a few weeks or months (3). 
The long-term impact of such correction is an attenuation of 
bone loss, a reduced risk of falling and fragility fractures (4-7). 
Intervention with pharmacological agents documented that 
early measurements in serum bone resorption markers predict 
the rate of bone loss (8) and the incidence of fragility fractures 
(9).  As recently reviewed (10), the predictive value of early 
change in bone biochemical markers is of particular interest 
for clinical research in nutrition. Indeed, studies comparing 
the effects of different foods on bone structural component 
outcomes, let alone on fragility fractures, are difficult or even 
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Abstract: Objective: To evaluate whether fortification of yogurts with vitamin D and calcium exerts an 
additional lowering effect on serum parathyroid hormone (PTH) and bone resorption markers (BRM) as 
compared to iso-caloric and iso-protein dairy products in aged white women at risk of fragility fractures. Design: 
A randomized double-blind controlled trial. Setting: A community dwelling home. Participants: Forty-eight 
women over 60 years (mean age 73.4). Intervention: Consumption during 84 days of two 125 g servings of either 
vitamin D and calcium-fortified yogurts (FY) at supplemental levels of 10 µg vitamin D3/d and 520 mg/d of 
calcium (total=800 mg/d), or non fortified control yogurts (CY) providing 280 mg/d of calcium. Measurements: 
Serum changes from baseline (D0) to D28, D56 and D84 in 25OHD, PTH and in two BRM: Tartrate-resistant-
acid-phosphatase-isoform-5b (TRAP5b) and carboxy-terminal-cross-linked-telopeptide of type-I-collagen (CTX).  
Results: The 10 years risk of major and hip fractures were 13.1 and 5.0%, and 12.9 and 4.2 %, in FY and CY 
groups, respectively. From D0 to D84, serum 25OHD increased (mean±SE) from 34.3±2.4 to 56.3±2.4 nmol/L 
in FY (n=24) and from 35.0±2.5 to 41.3±3.0 nmol/L in CY (n=24), (P=0.00001). The corresponding changes in 
PTH were from 64.1±5.1 to 47.4±3.8 ng/L in FY and from 63.5±4.6 to 60.7±4.2 ng/L in CY (P=0.0011). After 
D84, TRAP5b was reduced significantly (P=0.0228) and CTX fell though not significantly (P=0.0773) in FY 
compared to CY. Conclusion: This trial in aged white women living in a community dwelling home at risk for 
osteoporotic fractures confirms that fortification of dairy products with vitamin D3 and calcium should provide 
a greater prevention of secondary hyperparathyroidism and accelerated bone resorption as compared to non-
fortified equivalent foods. 
Key words: Osteoporosis prevention, nutritional intervention, calcium-vitamin D fortified yogurts, secondary 
hyperparathyroidism, bone resorption. 
Abbreviations: FY: vitamin D and calcium-fortified yogurt; CY: control (non fortified) yogurt; Ca: calcium; Pi: 
inorganic phosphate; 25OHD: 25-hydroxyvitamin D; PTH: parathyroid hormone; BRM: bone resorption marker; 
CTX: carboxy-terminal-cross-linked-telopeptide of type-I-collagen; TRAP5b: tartrate-resistant-acid-phosphatase-
isoform-5b; IGF-I: Insulin-like growth factor-I; BMD: bone mineral density; BTM: bone turnover markers; 
DXA: dual X-ray energy aborptiometry.
J Nutr Health Aging
Volume 19, Number 5, 2015
Received November 17, 2014
Accepted for publication January 7, 2015
impossible to conduct in randomized placebo-controlled trials 
of long duration (11).
Short-term evaluation is particularly appropriate for 
assessing the selective effects of food fortification on both 
skeleton trophic factors and biochemical bone turnover markers 
(BTMs). Such an assessment implies the comparison of the 
response to foods that only differ by the addition or not of 
the tested nutrient(s). This clinical investigation approach 
can be considered as lying within the conceptual scope of 
“Comparative Effectiveness Research (CER)” (12). So far, 
few studies have applied a CER design in the field of clinical 
nutrition, such as that comparing the effects of two plant-source 
forms of calcium supplements on bone mineral density  (13). 
In conformity with the CER concept, we recently published 
a randomized controlled trial in which consumption of vitamin 
D and Ca fortified yogurts, as compared to non fortified 
equivalent dairy products, exerted a greater positive impact 
on bone trophic factors and BTMs after 8 weeks (3). This 
randomized controlled trial was carried out in institutionalized 
elderly women (mean age: 86 years) with quite a low baseline 
vitamin D status, as documented by a serum level of 25OHD 
of 18 nmol/L (3). This concentration is well below the level 
of 50 nmol/L, considered by the Institute of Medicine (IOM) 
as meeting the requirements of 97.5 % of the North-American 
population (14), let alone the much higher level of 75 nmol/L 
estimated as adequate in the Endocrine Society Clinical 
Practice Guideline (15). 
Therefore, it remained to be documented that the same 
fortified dairy product could also favourably affect skeletal 
trophic factors and BTMs in women with a vitamin D 
insufficiency other than the deficiency documented in elderly 
women living in French nursing homes (3). This hypothesis 
was tested in a 12 week randomized controlled trial enrolling 
women over 60 (mean age: ~ 74 years) living in a community 
home in England. As compared to the previous study (3), the 
new cohort displayed a baseline 25(OH)D serum level about 
twice (~ 34 nmol/L) as high than that recorded in older French 
institutionalized women. Despite these substantial differences 
in age, environmental living conditions and baseline vitamin D 
status, the results presented here confirm the gain in efficacy of 




A total of 96 women living in a sheltered accommodation 
housing in Hull (England) were screened for eligibility.  The 
recruitment for eligibility started after the Research and 
Development review board of the Hull & East Yorkshire 
Hospital NHS Trust approved the protocol on April 23, 2012: 
“Permission for Research R1307”. One single investigator 
conducted the study, in accordance to the Helsinki Declaration, 
the Good Clinical Practices (GCPs) and in compliance with 
English national regulations. Of this initial group, 28 subjects 
did not fulfill the serum 25OHD and PTH inclusion criteria; 
10 subjects withdrew consent and 1 died.  Thus, 57 women 
responded to the inclusion criteria: aged >60 years, with a 
prior medical check-up suitable for research purposes, serum 
levels of 25OHD ≤ 20 ng/mL and PTH <150 ng/mL. They were 
enrolled between May 29, 2012 and July 18, 2012, all having 
given their informed consent. The age ranged from 61 to 90 
years, with mean (±SD) age 73.4 ± 7.5 years  (median: 73.4 
years). 
Exclusion criteria 
Exclusion criteria included concomitant diseases 
or any illness affecting Ca-Pi metabolism such as primary 
hyperparathyroidism; osteoporotic fracture during the 
year preceding the study; chronic gastrointestinal disease, 
chronic renal failure, hepatic and cardiac failure or cancer. 
Treatment during the last 6 months for osteoporosis or other 
bone diseases, including pharmaceutical agents such as: 
bisphosphonates, raloxifen, teriparatide, strontium ranelate 
and denosumab. Glucocorticoid therapy. Lactose intolerance. 
Participation in a clinical trial during the 3 months preceding 
the entry into the study. Confinement to bed. 
Design and conducted trial. 
It was a monocentric randomized double-blind comparative 
study conducted in two parallel groups, in which subjects were 
allocated to consume daily 2 yogurts of 125 g each, providing 
either 10 µg (400 IU) of vitamin D3 and 800 mg of elemental 
Ca (Fortified Yogurt = FY) or 0 µg of supplemental vitamin 
D3 and 280 mg of elemental Ca (Control Yogurt = CY) during 
84 days. Before the fortification process, both FY and CY 
contained 140 mg of milk Ca per serving. To fortify one type 
of yogurt (FY) vitamin D3 was added in powder form and 
Ca (+260 mg/serving) as citrate salt. Both vitamin D3 and Ca 
citrate were mixed with fruit (strawberry, cherry or apricot) 
preparation used as flavoring components to the two types (FY 
and CY) of yogurts. Yoplait France provided the yogurts. 
A random number table was used with blocks of four to 
determine the allocation sequence. The random allocation 
was centralized, computer-generated, and stratified by the 
investigating center. The two types of yogurts were presented 
in identical packs. In order to insure the blinding, they were 
designated with two code letters (A and B) and the code only 
broken after the statistical analysis had been fully completed. 
The two servings of 125 g of either type of yogurts daily 
provided similar amounts of proteins (FY: 7.8 g; CY: 8.0 g), 
energy (FY: 232 kcal; CY: 248 kcal), lipids (FY: 6.2 g; CY: 
6.5 g) and carbohydrates (FY: 33 g; CY: 36 g).  They were 
recommended to be consumed one at lunchtime, the other at 
dinner.
From the 57 enrolled subjects (CY: 29; FY: 28), 6 (3 in 
each group) left the study without any follow-up evaluation 
carried out. From the 51 participants (CY: 26; FY: 25), 3 
had to be excluded because of some major deviation from 
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the protocol due to the introduction of either osteoporosis 
treatment or vitamin D supplementation (CY: 2; FY: 1). Thus, 
in 48 subjects (24 in each group), serum analysis of 25OHD, 
PTH, CTX and TRAP5b were measured at all time points (D0, 
D28, D56 and D84) enabling the assessment of the changes in 
these 4 biochemical variables from the onset to the end of the 
intervention.    
Compliance and Satisfaction Evaluation  
A compliance and satisfaction form on the yogurt 
consumption was completed daily by each of the participants, 
and monthly by the dieticians and nurses of the sheltered 
accommodation center. The questionnaire included a question 
concerning how much yogurt was consumed and reason for any 
incomplete intake. At D28, D56 and D84, four questions on the 
satisfaction of consuming either type of yogurts were asked in 
relation to: flavor; pot size adapted to appetite; limitations of 
intake at both lunch and dinner; lack of interest in maintaining 
intake. 
Clinical assessment
Fracture risk evaluation. The 10 year risk of hip and major 
osteoporotic fracture of each participant was computed by 
using the probability model FRAX® (16) calibrated to the 
United Kingdom population. The prediction of fracture with the 
use of clinical risk factors alone in FRAX, i.e. without a DXA 
test, is comparable to the BMD measurement alone (17).
Dietary survey at baseline and during the intervention. Ca, 
proteins and energy intakes were assessed at baseline (D0) and 
at the end of the intervention (D84). Food consumption was 
recorded by 3-day dietary diaries (18). 
Sun exposure. The participants were asked to report if, 
at any time, they spent more than 20 minutes daily with 
uncovered arms exposed to the sun. 
Biochemical analysis
The blood samples were collected in the morning after an 
overnight fast and stored at -70o C until analysis. Serum Ca 
and inorganic phosphate (Pi) were measured by colorimetry 
(Roche Diagnostics, Rotkreuz, Switzerland). Serum 25OHD, 
PTH, CTX and TRAP5b, were measured by enzyme-linked 
immunosorbent assay (ELISA) on the Bio-Rad Microtech 
Microplate Reader. The following immunoassay kits were 
used: 25OHD, CTX and TRAP5b (Immunodiagnostics System, 
Fountain Hills, AZ, USA); PTH (Human Bioactive PTH Elisa 
kit, Immunotopics, San Clemente, CA, USA). The intra- 
assay and inter-assay variations including the variations for 
TRAP5b were less than 6.0 and 8.0%, respectively. Analytical 
measurements were made in duplicates for PTH, CTX and 
TRAP5b.
Statistical analysis
The main aim of the trial was to demonstrate that 
consumption of fortified as compared to non-fortified yogurts 
exerted more favorable effects on vitamin D status (increased 
serum 25OHD), secondary hyperparathyroidism (decreased 
serum PTH) and decreased BRMs (serum CTX and TRAP5b). 
Determination of the sample size was estimated from the 
effects on changes in serum TRAP5b. It was expected that 
a difference of 10 % in serum TRAP5b changes would be 
detected between the two groups with a power of 80 % and 
two-sided alpha of 0.05. Such a 10 % difference in change 
in TRAP5b required a sample of 15 participants per group, 
taking into account a standard deviation of inter-individual 
difference of 9.3% (19). 29 and 28 subjects in CY and FY 
groups, respectively, were eventually enrolled into the 
study and randomized. The data are expressed as mean ± 
SE. Differences between quantitative data measured at D0 
and changes from D0 to D84 were evaluated by the Mann-
Whitney U test or Student t test to determine whether or not the 
individual values were normally distributed. The differences in 
time courses (from D0 to D84), type of yogurts and interactions 
between time course and type of yogurts for serum 25(OH)D, 
PTH, CTX and TRAP5b were evaluated by repeated-measure 
analysis of variance (ANOVA) with adjustment by the Tukey’s 
test. Statistical analysis of the data was conducted by using 
SAS V9.2 (SAS Institut Inc, Cary, NC, USA) and STATA 
software version 9.2 (StataCorp LP, College Station TX, USA). 
In addition, chi-square tests were used (20) to compare the 
proportion of FY vs CY, with serum values of 25(OH)D ≥ 50 
nmol/L (the IOM sufficiency threshold (14)), and of PTH ≤ 46 
ng/L (the normal range limit) after 84 days of intervention. The 
P value <0.05 was considered statistically significant. 
 
Results
Characteristics at baseline (Day 0)
The demographic characteristics at the inclusion into the 
trial (D0) did not differ between the CY and FY randomized 
groups (Table 1). At baseline, using the FRAX questionnaire 
specifically adapted to the UK population, it appeared that 
the estimated 10-year risk of major osteoporotic fractures, or 
hip fracture alone, was not different between the CY and FY 
group (Table 1). The similarity FRAX scores fracture could 
be expected given that both quantitative and qualitative risk 
factors did not differ between the two groups. The dietary 
intakes of Ca, energy, proteins, carbohydrates and lipids, as 
recorded in 20 and 16 participants in the CY and FY group, 
respectively, did not differ significantly (Table 2). At baseline 
(D0), there was no significant difference in serum 25OHD, 
PTH, CTX and TRAP5b between the two groups (Table 3). 
Response to fortified foods
The time-dependent change in serum 25OHD was more 
pronounced in the FY than in the CY groups (Figure 1). After 
84 days it was about 4 times larger (P =0.00001) in FY than 
CY (Table 3). The rise serum 25(OH)D greater in FY than 
in CY at D84 was associated with a significantly (P=0.0011) 
greater decrease in serum PTH (Figure 2). The differences in 
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percent changes between 25(OH)D and PTH from D0 to D84 
are illustrated in Figure 3. At D84, the proportion of subjects 
with a serum level ≥ 50 nmol/L was 70.8% (17/24) and 16.7% 
(4/24) in the FY and CY groups, respectively (chi square test 
P<0.001). After the same intervention time, the proportion of 
subjects with a serum PTH level ≤ 46 ng/L was 58.3% (14/24) 
and 25% (6/24) in the FY and CY groups, respectively (chi 
square test P<0.05).     
Figure 1
Serum level of 25(OH)D in subjects consuming either non-
fortified (CY) or vitamin D and Ca-fortified (FY) yogurts
25OHD was determined in serum samples collected at baseline (D0), and 4 (D28), 8 (D56) 
and 12 (D84) weeks after the beginning of the intervention in subjects consuming either 
non-fortified control yogurts (CY) or fortified yogurts (FY) (means in nmol/L+/- SE). The 
dashed line corresponds to the serum 25OHD level considered as sufficient in the 2011 
IOM report (14). Number of subjects: 24 in each group. P=0.00001 by repeated-measures 
ANOVA for the difference between the two types of yogurts.
The more pronounced  fall in serum PTH in the FY group, 
compared to CY group, was associated with a significant 
reduction in serum TRAP5b (Figure 3). There was also a 
reduction in serum CTX, the other marker of bone resorption, 
though the difference between FY and CY did not reach 
the level of statistical significance (Figure 3). There was a 
significant interaction between the time course and the type of 
yogurt for serum 25OHD (Table 3), but not for serum PTH that 
also tended to fall in the CY group (Figure 2). 
Other monitored variables 
The Ca intake recorded by 3-day dietary diaries was 710±45 
at D0 and 869±44 mg/d at D84 in the CY group. It was 783±75 
at D0 and 1457±57 mg/d at D84 in the FY group. The calcium 
relative increase was 33 % and 115 % in the CY and FY group, 
respectively. Meanwhile, in both CY and FY groups, the 
consumption of energy and protein did not significantly differ 
between D0 and D84 (data not shown). 
Figure 2
Serum level of PTH in subjects consuming either non-fortified 
yogurts(CY) or vitamin D and Ca-fortified (FY) yogurts
PTH was determined in serum samples collected at baseline (D0), and 4 (D28), 8 (D56) 
and 12 (D84) weeks after the beginning of the intervention in subjects consuming either 
non-fortified control yogurts (CY) or fortified yogurts (FY) (means in ng/L+/- SE). 
The dashed line corresponds to the upper level of the normal range of PTH. Number of 
subjects: 24 in each group. P=0.0075 by repeated-measures ANOVA for the difference 
between the two types of yogurts.
The serum Ca, Pi, prealbumin, and albumin did not 
significantly change between D0 and D84 in either group. 
Likewise for body weight, systolic and diastolic blood pressure 
(data not shown).
Sun exposure. During the intervention, none of the subjects 
spent daily more than 20 minutes outdoors with their uncovered 
arms exposed to the sun. 
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Table 1
Participants’ Characteristics at Baseline : Demography and 
Fracture risk
CY Group  
(N= 24)
FY Group  
(N= 24)
Age (year) 72.8 (1.6) 74.3 (1.4)
Standing Height  (cm) 160.0 (1.4) 161.8 (1.2)
Body Weight (kg) 79.8 (3.2) 76.1 (2.7)
BMI (kg/m2) 31.1 (1.1) 29.2 (1.1)
10 Year Risk of Major Fractures (%) 1) 12.9 (1.2) 13.1 (0.9)
10 Year Risk of Hip Fracture (%) 1) 4.2 (0.8) 5.0 (0.9)
Values of control (CY) and fortified (FY) yogurt groups are means (SE); 1) Calculated 
from the WHO-FRAX rating scale, adapted to the UK population. No difference between 
CY and and FY group was statistically significant.; BMI: Body mass index.
Table 2
Participants’ Dietary Intakes at Baseline 
CY Group (N= 20) FY Group (N= 16)
Ca (mg/d) 710 (45) 782 (75)
Energy  (kcal/d) 1377 (48) 1379 (86)
Proteins (g/d) 60 (3) 61 (5)
Carbohydrates (g/d) 146 (8) 152 (12)
Lipids (g/d) 59 (3) 55 (4)
Values of control (CY) and fortified (FY) yogurt groups are means (SE); They were calcu-
lated by 3-day dietary diaries and were available in subgroups of randomized participants. 
No difference between CY and and FY group was statistically significant.
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Figure 3 
Percent change in serum 25OHD, PTH, CTX and TRAP5b 
after 84 days of consumption of control yogurts (CY) as 
compared to vitamin D and calcium-fortified yogurts (FY)
Values are means in percent after 84 days (D84-D0/D0 x 100) of intervention in subjects 
consuming non-fortified control (CY) and fortified yogurts (FY), respectively. ∆ = 
Difference in percent between CY and FY groups; Number of subjects: 24 in each group; 
P. Probability levels for the differences D84-D0, calculated either by the two-sided Student 
t test or by the Mann-Whitney U test, whether the values were normally distributed (PTH 
and TRAP5b) or not (CTX and 25OH). 
Acceptability and adherence  
The two types of yogurts were well tolerated. The 
acceptability in terms of flavor and portion size was considered 
as appropriate. The mean compliance throughout the 
intervention was more than 95% in both groups, despite the 




The serum biochemical pattern encompassing low vitamin 
D status, secondary hyperparathyroidism and increased bone 
resorption indices characterizes the insufficient supply of 
vitamin D associated with inadequate Ca intake. This pattern 
tends to be more frequently observed with aging. The related 
biochemical anomalies can be corrected within a few weeks 
or months by providing an adequate supply of both vitamin D 
and Ca. Such correction is associated with an attenuation of 
bone loss, a reduced risk of falling and osteoporotic fractures 
(4-7). These beneficial effects of vitamin D supplementation 
in conditions of deficiency or insufficiency can be observed 
with much lower-dose regimens than those that can be 
detrimental to bone health (21). Indeed, vitamin D supply can 
be inefficient in community-dwelling individuals with vitamin 
D sufficiency (22). Controversy on the outcome of vitamin D 
on bone health, fragility fractures and falls can be explained, 
at least in part, by differences between: supplemental doses; 
duration of supplementation; ethnic/racial target populations; 
baseline vitamin D status (21-30). Furthermore, interpretation 
in terms of inadequacy/adequacy of serum 25OHD baseline 
levels and-or intervention-induced changes in response to 
supplemental vitamin D can differ when related to the concept 
of the “Estimated Average Requirement (EAR) or to the 
“Recommended Dietary Allowance (RDA)“, as well as to the 
method of assessment (31, 32). The notion of inadequacy/
adequacy of the vitamin D status is still much more difficult 
to delineate when putative extraskeletal effects are considered. 
Indeed, from association findings mostly, it has been 
suggested that vitamin D insufficiency could be implicated as 
a causal or at least as a contributing factor to several chronic 
diseases including type 2 diabetis, cardiovascular disease, 
some cancers, autoimmune and infectious disorders (15, 33). 
Cognitive functions have also been positively associated with 
the vitamin D status (34-37). This link could be implicated in 
the risk of falling that might be, at least in part, explained by 
some deficit in both attention and executive functions. The 
direct causal relationship  between vitamin D and the various 
chronic diseases mentioned above remains to be established in 
Table 3
Participants’ Serum Biochemistry at Baseline (D0), 28 (D28), 56 (D56) and 84 (D84) Days of Control (CY) or Fortified (FY) 
Yogurt Comsumption a

















































































































 0.0228 0.755 0.923 0.550
a Values are means (SE); Pb Probablity levels for the differences D84-D0, calculated either by the two-sided Student t test or by the Mann-Whitney U test, whether the values we.re nor-
mally distributed (PTH and TRAP5b) or not (CTX and 25OHD); P c Probability level by repeated-measures ANOVA for difference in time course (D0 to D84); P d Probability level by 
repeated-measures ANOVA for difference between control (CY) and fortified (FY) yogurts; P e Probability level by repeated-measures ANOVA for interaction between  time course (D0 
to D84) and type (CY vs. FY) of yogurts.
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appropriately designed prospective studies.      
The foregoing randomized controlled trial was essentially 
focused on the effects of two nutrients on bone-related 
metabolism. It confirms the results of a previous similar 
study (3) showing that fortification of the same dairy product 
with vitamin D3 and Ca, as compared to the identical non 
fortified food, enhances vitamin D status, corrects secondary 
hyperparathyroidism and, concomitantly, reduces biochemical 
markers of bone resorption. This confirmation, with results 
supported by intention-to-treat analysis, as in the previous 
study (3), is of interest since these two trials differed on several 
important demographic and environmental aspects. 
The former trial was carried out in institutionalized women 
with mean age 86 (3). These participants were entirely 
dependent on long-term care facilities. The nursing staff 
provided a comprehensive assistance during the trial, including 
the regular delivery of meals to the participants. In contrast, 
in the current study, the participants were younger, with mean 
age 74. They were free living in sheltered accommodation 
where tenants are able to look after themselves with a degree 
of independence. This setting implied that their eating habits 
could be maintained. Although the new reported outcomes 
are qualitatively quite similar to those of the previous study 
(3), there are some quantitative differences between the two 
trials that deserve to be commented in relation with the distinct 
demographic and environmental conditions. The better vitamin 
D status in the current study, as compared to the other “twin“ 
study (3), could be putatively explained by factors such as age 
(74 vs. 86 years) and-or living conditions (community dwelling 
vs. nursing home) that may have influenced the supply of 
vitamin D from both cutaneous and food sources (38). 
The changes in the serum 25OHD in response to 10 µg 
supplemental vitamin D3, as compared to the non fortified 
yogurts, were at D56 less important in the present study (FY: 
+19.9; CY: +4.6 nmol/L, difference = +15.3 nmol/L) than in 
the previous report (3), (FY: +25.3; CY: +5.2: difference = 
+20.1 nmol/L). This 24% reduced response could be accounted 
for by the known inverse relationship between the baseline 
serum level of 25(OH)D and its increment following an oral 
intake of supplemental vitamin D3 (39, 40). Indeed, at D0, 
the level of serum 25OHD in the FY group was about 80% 
higher in the present report (FY Group : 34.1±2.4 nmol/L) 
than in the previous comparable intervention study (FY 
Group: 19.2±1.2 nmol/L) testing the same dairy product (3). 
In the present trial, after 56 days of FY consumption, the mean 
serum 25OHD (54 nmol/L) was above the level (50 nmol/L) 
considered by the IOM, at least for skeletal health, as covering 
the vitamin D requirements of ≥ 97.5 % of the North-American 
population (14). Figure 1 illustrates the time-dependent 
changes in serum 25OHD in relation with the 50 nmol/L level 
for sufficient concentration as stated in the IOM guidelines 
(14).  Accordingly, in the FY group, the mean serum 25OHD 
concentration overcrosses this level between D28 and D56. At 
that time, as illustrated in Figure 2, the serum PTH level was 
still above the upper limit of the normal range. However, at 
D84, given the additional 4 weeks of FY consumption, serum 
PTH fell into the normal range, suggesting that correction of 
secondary hyperparathyroidism was achieved after 3 months of 
FY consumption  (Figure 2). The reduction of the two markers 
of bone resorption, CTX and TRAP5b, may be interpreted as 
the functional consequence of the reduced extracellular level of 
PTH. Besides the 10 µg of supplemental vitamin D3, the 86 % 
higher Ca intake in the FY group as compared to the CY group 
(mean: 1457 vs. 783 mg/d) could have substantially contributed 
to the control of secondary hyperparathyroidism. 
As recently reviewed (41), high PTH concentration has 
been associated with increased risk of cardio-vascular diseases. 
Among intermediate risk factors, increased blood pressure 
could be implicated in this association. In our 3 month 
randomized trial both systolic and diastolic blood presssure 
remained stable despite a marked fall in serum PTH in the 
subjects consuming vitamin D an Ca fortified yogurt. Strengths 
and limitations. 
The strengths of this study include a three month 
randomized controlled trial comparing the effects of Ca and 
vitamin D fortification of a dairy product in women over 60 
living in community dwelling accommodation on the relation 
between the serum level of 25OHD, PTH and two biochemical 
markers of bone resorption. The study responds to the concept 
of comparative effectiveness research, since the fortified 
yogurts were compared to identical but non-fortified dairy 
products. Another strength is the intention-to-treat analysis 
supporting the results with the demonstration of the vitamin 
D status improvement associated with the reduction of both 
secondary hyperparathyroidism and bone resorption markers 
in women at moderate risk of fragility fractures. The good 
compliance to the consumption of the two compared food 
products during three months can also be considered as an asset 
in this clinical trial.       
A limitation was the uncomplete data related to the 
dietary survey. Indeed, the 3-day dietary diaries to assess the 
spontaneous calcium and macronutrient intakes at baseline 
and during the intervention were not reliably completed by 
all of the enrolled participants. Therefore, it cannot be ruled 
out that uneven bone-related food consumption might have 
influenced the magnitude of the differences in the reported 
biochemical variables between the two experimental groups. 
Another limitation is the difficulty to control the vitamin 
D supply from both cutaneous and food sources. The rise 
in the serum level of 25OHD in the control group reflects 
this difficulty. However, it also underscores the importance 
of quantifying the actual effect of the tested fortification as 
compared to an identical non-fortified product in parallel 
randomized control trials. The reported mean rise in serum 
25OHD of 22 nmol/L, modifying the vitamin D status from 
insufficiency (34 nmol/L) to sufficiency (56 nmol/L) after 3 
months of 10 µg/d of vitamin D3 supplied by the consumption 
of fortified yogurts was determined in white postmenopausal 
women living in a community dwelling home. This dose-
response relationship may not apply to other ethnic or racial 
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population of postmenopausal women living in similar housing 
communities (30).   
Conclusions. The daily consumption of two fortified yogurts 
for three months providing 520 mg of Ca and 10 µg (400 IU) of 
vitamin D3 daily, compared to a non fortified equivalent dairy 
product, increased the mean serum level of 25OHD above 50 
nmol/L, almost controlled secondary hyperparathyroidism and 
reduced serum markers of bone resorption. This comparative 
effectiveness clinical trial confirms the usefulness of a 
nutritional approach consisting in enriching dairy products with 
Ca and vitamin D3 in order to prevent the acceleration of bone 
turnover in women at risk of fragility fractures. 
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